23 Feb Oxford Biomedica
Dave Backer, Chief Commercial Officer
April 20 | 12:15pm | Gaudi 3 Ballroom
Oxford, United Kingdom
A leading, fully integrated, cell and gene therapy group focused on developing life-changing treatments for serious diseases, Oxford Biomedica is your trusted partner of choice for viral vector development scale-up, analytics, and GMP processing. Leverage our expertise, state-of-the-art bioprocessing facilities, and purpose built laboratories to help achieve commercialization of your viral vector-based products. Using LentiVector®, our sector leading lentiviral vector platform, Oxford Biomedica develops in vivo and ex vivo products both in-house and with partners, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, and Imperial Innovations. Additionally, Oxford Biomedica has a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine, AZD1222.